Ludwig Institute for Cancer Research Limited

Memorial Sloan Kettering Cancer Center

Institute of Molecular Biology and Genetics National Academy of Science of Ukraine

Cornell University

Sloan-Kettering Institute for Cancer Research

Ucl Business Plc

Institute for Molecular Biology and Genetics National Academy of Science of Ukraine

Ivan Tarasovich Gout

Michael Derek Waterfield

Ian D Hiles

Ritu Bala Dhand

Michael J Fry

Lloyd J Old

Gerd J Ritter

Kenneth O Lloyd

George Mark

Anne Murray

Peter J Parker

Masayuki Otsu

George Panayoutou

Serhiy Souchelnytskiy

Stefano Volinia

Valeriy Filonenko

Beatrice Yin

Ramziya Kiyamova

Kenta Hara

Mike Waterfield

Kazu Yonezawa

Yao-tseng Chen

Matthew J Scanlan

Elisabeth Stockert

Ali O Gure

Lloyd Old

Ivan Nemazanyy

Kazuyoshi Yonezawa

Ganna Panasyuk

Alexander Zhyvoloup

George Panayotou

Peter End

Masato Kasuga

The present invention relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy

Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided.

Membrane transporter NaPi2b (SCL34A2) epitope antibodies

The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.

Truncated variant of the mammalian target for rapamycin (MTOR) protein

Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

A novel S6 kinase, p70&#x3b2;is described, along with methods of making and using p70&#x3b2;protein and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70&#x3b2;protein and/or its ligands.

Identification and functional characterization of a novel ribosomal S6 protein kinase

This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.

Method for determining expression of a PI3 kinase gene

The invention provides methods for diagnosing cancer including breast cancer, based on the identification of certain breast cancer-associated polypeptides as antigens that elicit immune responses in breast cancer. The identified antigens can be utilized as markers for diagnosing breast cancer, and for following the course of treatment of breast cancer.

Breast cancer antigens

A novel S6 kinase, p70&bgr; , is described, along with methods of making and using p70&bgr; and related nucleic acids. The invention also discloses methods of identifying agents which modulate the activity of p70&bgr; and/or its ligands.

Polypeptides having kinase activity, their preparation and use

The invention provides for a method to inhibit the binding between the p85 and p110 subunits of said PI3-kinase and thus a method to modulate PI3-kinase activity and modulate the response of cells to external stimuli. In particular, disabling, by conventional means, residues located in the inter-SH2 domain of said p85 subunit, specifically a region containing amino acid residue 478 to amino acid residue 513 of p85.alpha. subunit, or amino acid residue 445 to amino acid residue 485 of p85.beta. subunit of said PI3-kinase. Interference with these binding regions will affect binding between the subunits and results in inhibiting PI3-kinase activity. This invention further relates to a methods to modulate the serine kinase activity of the PI3-kinase which can be achieved by disabling the DRHNSN sequence of the p110 subunit and can also be used to effect changes in overall PI3-kinase activity. This invention is further related to an (ant)agonist which affects serine kinase activity of PI3-kinase. An agonist is provided which stimulates the phosphorylation of the p85 subunit at the serine residue at position 608, wherein phosphorylation at the serine residue indirectly results in inhibiting PI3-kinase activity.

Methods to inhibit serine kinase activity and to alter intersubunit

Growing community of inventors

London, United Kingdom

Ivan Tarasovich Gout